Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022

SELL
$30.27 - $49.22 $432,861 - $703,846
-14,300 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$42.11 - $73.26 $602,173 - $1.05 Million
14,300 New
14,300 $706,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $641M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Boulder Hill Capital Management LP Portfolio

Follow Boulder Hill Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boulder Hill Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Boulder Hill Capital Management LP with notifications on news.